|
|
 |
 |
| |
 Printable version |
Analysis of medical prescription of granulocyte-colony stimulating factors in 19 French anticancer centers |
Bulletin du Cancer. Volume 85, Number 12, 1043-8, Décembre 1998, Articles originaux
|
 Résumé
Article gratuit
|
Author(s) : Groupe de pharmaciens de la Fédération nationale des centres de lutte contre le cancer |
Summary : Medical prescription of hematopoietic growth factors (HGF) was analysed in 19 anticancer french centers during 2 months. About 4% of anticancer chemotherapeutic cycles prescribed during this period were supported by HGF prescription. The mean duration of treatment was 8 days. Among the 755 collected prescriptions, two tumor localizations represented about 50% of the prescriptions: malignant non Hodgkin lymphomas and breast cancer. The other main localizations concerned adult or pediatric soft tissue sarcomas (18%), testicular cancer (7%) and gynecologic tumors (6%). The prescription for primary prophylaxis for febrile neutropenia remains the main use of HGF (44%). The respect of the guidelines established by the Fédération nationale des centres de lutte contre le cancer was analyzed. Overall, 66% of the prescriptions were in adequation with these guidelines. Whereas the consommation of HGF decreased in the 19 considered institutions, it did not reach a plateau and could decrease in institutions which are awaked to the international and national recommendations. |
Keywords : hematopoietic growth factors, Standards Options Recommendations, consommation. |
|
